Amneal Pharmaceuticals, Inc. AMRX Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net
Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestRateCashFlowHedgeGainLossReclassifiedToEarningsNet.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s interest rate cash flow hedge gain (loss) reclassified to earnings, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s interest rate cash flow hedge gain (loss) reclassified to earnings, net?
- Amneal Pharmaceuticals, Inc. (AMRX) reported interest rate cash flow hedge gain (loss) reclassified to earnings, net of -$2.88M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s interest rate cash flow hedge gain (loss) reclassified to earnings, net changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s interest rate cash flow hedge gain (loss) reclassified to earnings, net decreased by 144.7% year-over-year, from $6.44M to -$2.88M.
- What does interest rate cash flow hedge gain (loss) reclassified to earnings, net mean?
- This reflects the reclassification of gains or losses from accumulated other comprehensive income into earnings when the hedged interest rate risk impacts the income statement. It provides insight into the effectiveness and financial impact of interest rate hedging strategies.